Dominant cytotoxic T lymphocyte response to the immediate-early trans-activator protein, BZLF1, in persistent type A or B Epstein-Barr virus infection.

Five healthy human leukocyte antigen-B8 (HLA-B8)-positive virus carriers were studied to investigate the CD8+ cytotoxic T lymphocyte (CTL) response to an HLA-B8-restricted peptide, RAKFKQLLQ, located in the Epstein-Barr virus (EBV) immediate-early trans-activator protein, BZLF1. Of the 5 virus carriers, 4 were infected with type A and 1 with type B EBV. Using limiting-dilution analysis of peripheral blood mononuclear cells, a high RAKFKQLLQ-specific CTL precursor frequency was demonstrated after specific peptide or autologous lymphoblastoid cell line stimulation in both type A and type B EBV carriers. The RAKFKQLLQ-specific CTL precursor frequencies in all 5 persons were at least as dominant as those observed with two other EBV-associated, HLA-B8-restricted latent epitopes, FLRGRAYGL and QAKWRLQTL. These findings show that healthy virus carriers maintain a high frequency of BZLF1-specific memory T cells, potentially to control virus spread from lytically infected cells.

[1]  F. Mandelli,et al.  Transcription of latent and replicative Epstein‐Barr‐virus genes in bone‐marrow and peripheral‐blood mononuclear cells of healthy donors , 1997 .

[2]  Rekha Khanna,et al.  Recruitment during infectious mononucleosis of CD3+CD4+CD8+ virus-specific cytotoxic T cells which recognise Epstein-Barr virus lytic antigen BHRF1. , 1996, Virology.

[3]  S. Burrows,et al.  Copyright � 1995, American Society for Microbiology Immune Regulation in Epstein-Barr Virus-Associated Diseases , 2022 .

[4]  S. Modrow,et al.  Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus , 1995, Journal of virology.

[5]  H. Stein,et al.  Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. , 1995, Blood.

[6]  S. Burrows,et al.  Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Becker,et al.  Expression of proteins encoded by Epstein-Barr virus trans-activator genes depends on the differentiation of epithelial cells in oral hairy leukoplakia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Perricaudet,et al.  Detection of anti‐epstein‐barr‐virus transactivator (ZEBRA) antibodies in sera from patients with nasopharyngeal carcinoma , 1991, International journal of cancer.

[9]  J. Levy,et al.  Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes. , 1991, Clinical and experimental immunology.

[10]  S. Burrows,et al.  Patterns of reactivity of Epstein-Barr virus-specific T cells in A-type donor cultures after reactivation with autologous A- or B-type transformants. , 1990, Cellular immunology.

[11]  I. Ernberg,et al.  Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Epstein,et al.  In vitro analysis of the epstein‐barr virus: Host balance in long‐term renal allograft recipients , 1985, International journal of cancer.

[13]  M. Epstein,et al.  A re‐examination of the epstein‐barr virus carrier state in healthy seropositive individuals , 1985, International journal of cancer.

[14]  N. Raab-Traub,et al.  Epstein-Barr virus replication in oropharyngeal epithelial cells. , 1984, The New England journal of medicine.